loading

Our Story: Pioneering Automated Hypoglycemia Prevention to Transform Diabetes Care

Our Story

From Personal Experience to Global Mission

Jaifry was founded in 2021 by Mr. Mohamed Al-Jaifry, who lives with Type 1 Diabetes, after surviving a severe hypoglycemic event that nearly cost him his life. This personal tragedy sparked a passion to develop a solution that could prevent such dangerous situations for millions of people with diabetes worldwide.

What started as a research project evolved into a mission-driven company with a clear vision: eliminating the fear and danger of severe hypoglycemia through innovative technology that acts as an automated safety net.

Jaifry Founding Team
Jaifry Research Lab

Scientific Innovation Meets Compassionate Care

Our journey began with a simple question: Why can't we create a device that not only detects dangerous low blood sugar but also treats it automatically before it becomes life-threatening?

After three years of intensive R&D, we created the Jaifry System – a revolutionary integration of Continuous Glucose Monitoring (CGM), predictive AI algorithms, and automated glucagon delivery that provides 24/7 protection against severe hypoglycemia.

Leadership Team

Mr. Mohamed Al-Jaifry

Mr. Mohamed Al-Jaifry

CEO & Founder
PhD in Biomedical Engineering. Former VP of Medical Devices with over 15 years of experience in diabetes technology and 12 patents in medical device innovation.
Dr. Robert Chen

Dr. Robert Chen

Chief Technology Officer
PhD in Biomedical Engineering, MIT

Expert in sensor technology with over 20 patents. Previously led sensor development, developing industry-leading CGM systems.

Dr. James Wilson

Dr. James Wilson

Chief Medical Officer
MD, Harvard Medical School

Board-certified endocrinologist with 12 years of clinical practice specializing in diabetes. Former Director of Diabetes Care.

Michael Kingston

Mr. Michael Kingston

Chief Operating Officer
MBA, Wharton School of Business

Former Manufacturing Director with expertise in scaling medical devices and global supply chain management.

Arthur Rodriguez

Mr. Arthur Rodriguez

Chief Regulatory Officer
JD, Law School

Former Regulatory Affairs specialist with extensive experience navigating complex approval processes in international markets.

Dr. David Ray

Dr. David Ray

VP of Research & Development
PhD in Chemical Engineering

Specialist in drug formulation and delivery systems. Led the development of the liquid glucagon formulation used in Jaifry.

Our Values

Patient Safety First

Every decision we make prioritizes patient safety, comfort, and quality of life. We involve patients in the design process and constantly seek feedback to improve our products.

Scientific Excellence

We base our technology on rigorous scientific research and clinical evidence. Our commitment to excellence drives us to maintain the highest standards in all our developments.

Compassionate Innovation

We understand the human impact of diabetes and innovate with empathy. Our technology is designed not just to treat a condition, but to improve lives and reduce burdens.

Ethical Responsibility

We adhere to the highest ethical standards in all our operations, from R&D to manufacturing and marketing. Patient trust is our most valuable asset.

Our Journey

2021

Company Founded

Jaifry was established with a mission to prevent severe hypoglycemia through automated detection and treatment. Secured initial seed funding of $5 million from visionary healthcare investors.

2022

Prototype Development

Developed the first functional prototype and filed 12 core patents for sensor technology and glucagon formulation. Established research partnerships with three leading universities.

2023

Pre-clinical Success

Completed animal studies showing 99.2% detection accuracy and safety of the automated glucagon delivery system. Raised $25 million in Series A funding to accelerate development.

2024

Regulatory Milestones

Submitted pre-IDE package to the FDA and received positive feedback. Established a GMP-compliant manufacturing facility and began preparations for clinical trials.

Our Achievements

12
Patents Filed
99.2%
Detection Accuracy
$45M
Total Funding
25+
Research Partners

Awards & Recognition

Award Organization Year
Medical Tech Innovation Award Medical Device Association 2023
Pioneering Technology Award Diabetes Technology Society 2023
Patient Safety Innovation Award Healthcare Innovation Alliance 2022
Most Promising Startup Biotech Innovation Forum 2022

Our Partners

We collaborate with leading institutions to advance diabetes care and bring innovative solutions to patients worldwide.